title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
Report Forecasts Promising Future for Alzheimer's Disease Market with New Therapeutic Approaches | Brandessence Market Research,20230515T093200,https://www.prnewswire.com/news-releases/report-forecasts-promising-future-for-alzheimers-disease-market-with-new-therapeutic-approaches--brandessence-market-research-301824407.html,AZN,0.03478,Neutral,0.017283
"Geographic Atrophy Market to Boost Significantly, Assesses DelveInsight | Key Companies Active in the Domain - Novartis, Annexon, Apellis, Ionis, Astellas, Gyroscope, Genentech, Aviceda, Iveric Bio",20230628T210100,https://www.prnewswire.com/news-releases/geographic-atrophy-market-to-boost-significantly-assesses-delveinsight--key-companies-active-in-the-domain---novartis-annexon-apellis-ionis-astellas-gyroscope-genentech-aviceda-iveric-bio-301865699.html,AZN,0.077426,Neutral,-0.075581
"The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma | DelveInsight",20231122T220100,https://www.prnewswire.com/news-releases/the-evolving-market-dynamics-of-b-cell-lymphomas-diffuse-large-b-cell-lymphoma-follicular-lymphoma-chronic-lymphocytic-leukemia-mantle-cell-lymphoma-marginal-zone-lymphoma-waldenstrom-macroglobulinemia-and-burkitt-lymphoma--301995626.html,AZN,0.039505,Neutral,0.022299
Emergent BioSolutions Reports Financial Results For Third Quarter 2022,20221108T211600,https://www.globenewswire.com/news-release/2022/11/08/2551487/33240/en/Emergent-BioSolutions-Reports-Financial-Results-For-Third-Quarter-2022.html,AZN,0.049861,Neutral,-0.007995
Emergent BioSolutions  ( EBS )  Q2 2022 Earnings Call Transcript,20220802T033035,https://www.fool.com/earnings/call-transcripts/2022/08/01/emergent-biosolutions-ebs-q2-2022-earnings-call-tr/,AZN,0.006948,Neutral,-0.072951
Emergent BioSolutions Reports Financial Results for Second Quarter 2022,20220801T200500,https://www.globenewswire.com/news-release/2022/08/01/2489875/33240/en/Emergent-BioSolutions-Reports-Financial-Results-for-Second-Quarter-2022.html,AZN,0.021728,Neutral,0.011678
3 Monkeypox Stocks That Soared Last Week,20220523T091300,https://www.fool.com/investing/2022/05/23/3-monkeypox-stocks-that-soared-last-week/,AZN,0.05333,Bearish,-0.554367
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Koninklijke Philips  ( NYSE:PHG ) ,20241028T103251,https://www.benzinga.com/news/24/10/41569352/why-lenz-therapeutics-shares-are-trading-higher-by-around-18-here-are-20-stocks-moving-premarket,AZN,0.071357,Neutral,0.092635
48 Stocks Moving In Friday's Mid-Day Session,20220429T162716,https://www.benzinga.com/news/22/04/26904587/48-stocks-moving-in-fridays-mid-day-session,AZN,0.033034,Neutral,0.002041
70 Biggest Movers From Friday,20220502T094646,https://www.benzinga.com/news/22/05/26923653/70-biggest-movers-from-friday,AZN,0.026319,Neutral,0.005479
"Global Tissue Banking Market to Exhibit Growth at a Considerable CAGR of ~6% by 2030, Assesses DelveInsight",20240409T214100,https://www.prnewswire.com/news-releases/global-tissue-banking-market-to-exhibit-growth-at-a-considerable-cagr-of-6-by-2030-assesses-delveinsight-302110459.html,AZN,0.045962,Neutral,0.036735
"Drug-Eluting Balloons Global Market is Expected to Expand at a Healthy Growth Rate of ~8% by 2028, Predicts DelveInsight",20240124T220100,https://www.prnewswire.com/news-releases/drug-eluting-balloons-global-market-is-expected-to-expand-at-a-healthy-growth-rate-of-8-by-2028-predicts-delveinsight-302042856.html,AZN,0.025985,Neutral,0.033663
"Heart Failure Treatment Drug Market to Accelerate Immensely by 2032, Predicts DelveInsight",20240115T220500,https://www.prnewswire.com/news-releases/heart-failure-treatment-drug-market-to-accelerate-immensely-by-2032-predicts-delveinsight-302034593.html,AZN,0.046861,Neutral,0.08891
"Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors",20231016T115000,https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-appoints-life-science-industry-leaders-jeremy-bender-teresa-bitetti-and-david-meek-to-its-board-of-directors-301957344.html,AZN,0.044386,Neutral,0.041683
"Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors",20231016T115000,https://www.newswire.ca/news-releases/fusion-pharmaceuticals-appoints-life-science-industry-leaders-jeremy-bender-teresa-bitetti-and-david-meek-to-its-board-of-directors-816998848.html,AZN,0.044386,Neutral,0.041683
Aquestive  ( AQST )  to Report Q2 Earnings: What's in Store?,20230726T105300,https://www.zacks.com/stock/news/2127563/aquestive-aqst-to-report-q2-earnings-whats-in-store,AZN,0.113329,Neutral,0.0
Colorectal Cancer Treatment Drug Market to Show Immense Growth During the Study Period  ( 2019-2032 )  | DelveInsight,20231121T220100,https://www.prnewswire.com/news-releases/colorectal-cancer-treatment-drug-market-to-show-immense-growth-during-the-study-period-20192032--delveinsight-301994315.html,AZN,0.069227,Neutral,-0.026334
"Hypertension Market to Accelerate Positively, Estimates DelveInsight | Key Companies Active in the Market - Novartis, Bayer, Merck, Insmed, Acceleron, AbbVie, Alnylam, Apnimed, AstraZeneca, Gossamer Bio",20230719T210100,https://www.prnewswire.com/news-releases/hypertension-market-to-accelerate-positively-estimates-delveinsight--key-companies-active-in-the-market---novartis-bayer-merck-insmed-acceleron-abbvie-alnylam--apnimed-astrazeneca-gossamer-bio-301880558.html,AZN,0.074306,Neutral,0.079746
"Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period  ( 2019-2032 ) , Assesses DelveInsight | Leading Companies - Amgen, Novartis, AbbVie, BMS, Clovis Oncology, Cardiff Oncology, Roche, Daiichi Sankyo",20231004T210100,https://www.prnewswire.com/news-releases/small-cell-lung-cancer-market-to-accelerate-substantially-during-the-study-period-20192032-assesses-delveinsight--leading-companies----amgen-novartis-abbvie-bms-clovis-oncology-cardiff-oncology-roche-daiichi-sankyo-301946615.html,AZN,0.065268,Neutral,-0.046141
"Pancreatic Endocrine Tumor Market is Expected to Expand at a Healthy Growth Rate by 2032, Assesses DelveInsight | Key Companies - Merck, Theradex, SynerGene, Mirati, Novartis, Syntrix Biosystems, Eli Lilly, Boehringer Ingelheim",20230803T210100,https://www.prnewswire.com/news-releases/pancreatic-endocrine-tumor-market-is-expected-to-expand-at-a-healthy-growth-rate-by-2032-assesses-delveinsight--key-companies---merck-theradex-synergene-mirati-novartis-syntrix-biosystems-eli-lilly-boehringer-ingelheim-301892397.html,AZN,0.041466,Neutral,-0.038441
"Neuropathy Pain Treatment Market size to grow by USD 5.84 billion from 2023 to 2028, North America accounts for 33 ... - PR Newswire",20231214T221500,https://www.prnewswire.com/news-releases/neuropathy-pain-treatment-market-size-to-grow-by-usd-5-84-billion-from-2023-to-2028--north-america-accounts-for-33-of-market-growth--technavio-302015282.html,AZN,0.078099,Neutral,0.0
"Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer - Bright Minds Biosciences  ( NASDAQ:DRUG ) ",20221123T163529,https://www.benzinga.com/pressreleases/22/11/g29842256/bright-minds-biosciences-appoints-drug-development-executive-mark-a-smith-m-d-ph-d-as-chief-medica,AZN,0.040969,Neutral,-0.067624
"Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer",20221123T163500,https://www.globenewswire.com/news-release/2022/11/23/2561793/0/en/Bright-Minds-Biosciences-Appoints-Drug-Development-Executive-Mark-A-Smith-M-D-Ph-D-as-Chief-Medical-Officer.html,AZN,0.042723,Neutral,-0.067769
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug - Black Diamond Therapeutic  ( NASDAQ:BDTX ) ,20240923T154340,https://www.benzinga.com/general/biotech/24/09/40984991/black-diamond-therapeutics-lead-drug-candidate-shows-initial-anti-tumor-activity-in-certain-type-,AZN,0.209365,Neutral,0.0
"Cell-Free DNA Mutation Diagnostics Market to Surge to US$ 81,584.2 Million by 2034, Growing at a CAGR of 24.9% | Fact.MR Report",20241205T110000,https://www.benzinga.com/pressreleases/24/12/g42334329/cell-free-dna-mutation-diagnostics-market-to-surge-to-us-81-584-2-million-by-2034-growing-at-a-cag,AZN,0.05387,Neutral,0.074754
"Breast Cancer Monoclonal Antibodies Market to grow by USD 15 billion from 2022 to 2027, North America to account ... - PR Newswire",20230918T091500,https://www.prnewswire.com/news-releases/breast-cancer-monoclonal-antibodies-market-to-grow-by-usd-15-billion-from-2022-to-2027-north-america-to-account-for-42-of-market-growth---technavio-301929309.html,AZN,0.043108,Neutral,0.0
"Cutaneous Melanoma Market is Predicted to Exhibit Remarkable Growth, Predicts DelveInsight | Key Companies - Merck, Amgen, Anaveon, Eisai, Regeneron, BMS, AstraZeneca, Seagen, Novartis, Eli Lilly and Company",20230724T210100,https://www.prnewswire.com/news-releases/cutaneous-melanoma-market-is-predicted-to-exhibit-remarkable-growth-predicts-delveinsight--key-companies---merck-amgen-anaveon-eisai-regeneron-bms-astrazeneca-seagen-novartis-eli-lilly-and-company-301883725.html,AZN,0.02692,Neutral,0.029117
Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight,20230703T210100,https://www.prnewswire.com/news-releases/bispecific-antibody-clinical-trial-pipeline-appears-robust-with-250-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-301868673.html,AZN,0.020404,Neutral,0.115855
Antibody-drug Conjugates Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain,20230626T210100,https://www.prnewswire.com/news-releases/antibody-drug-conjugates-clinical-trial-pipeline-experiences-momentum-delveinsight-estimates-a-diverse-pipeline-comprising-180-companies-working-in-the-domain-301862784.html,AZN,0.062651,Neutral,0.067013
Gilead Sciences  ( GILD )  Q4 2022 Earnings Call Transcript,20230203T020023,https://www.fool.com/earnings/call-transcripts/2023/02/02/gilead-sciences-gild-q4-2022-earnings-call-transcr/,AZN,0.004354,Neutral,0.137153
"With 14.1% CAGR, Monoclonal Antibody Therapy Market Size Worth USD 451.89 Billion by 2028",20230130T105418,https://www.benzinga.com/pressreleases/23/01/g30618366/with-14-1-cagr-monoclonal-antibody-therapy-market-size-worth-usd-451-89-billion-by-2028,AZN,0.035983,Neutral,0.073894
"Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know - iShares Biotechnology ETF  ( NASDAQ:IBB ) , BondBloxx ETF Trust BondBloxx BB-Rated USD High Yield Corporate Bond ETF  ( ARCA:XBB ) ",20221101T200154,https://www.benzinga.com/general/biotech/22/11/29508633/provention-bios-second-try-apelliss-eye-disorder-drug-review-3-adcom-verdicts-and-more-novembers-,AZN,0.09402,Neutral,-0.05114
Regenerative Medicine Market is projected to grow at a CAGR of 18.40% by 2033: Visiongain Reports Ltd,20230405T110013,https://www.benzinga.com/pressreleases/23/04/g31675058/regenerative-medicine-market-is-projected-to-grow-at-a-cagr-of-18-40-by-2033-visiongain-reports-lt,AZN,0.028798,Neutral,0.0
Regenerative Medicine Market is projected to grow at a CAGR of 18.40% by 2033: Visiongain Reports Ltd,20230313T110000,https://www.benzinga.com/pressreleases/23/03/g31315741/regenerative-medicine-market-is-projected-to-grow-at-a-cagr-of-18-40-by-2033-visiongain-reports-lt,AZN,0.028798,Neutral,0.0
MIMEDX Welcomes Kate Surdez as Chief Human Resources Officer,20220718T133523,https://www.benzinga.com/pressreleases/22/07/g28100211/mimedx-welcomes-kate-surdez-as-chief-human-resources-officer,AZN,0.196877,Neutral,0.121782
MIMEDX Welcomes Kate Surdez as Chief Human Resources Officer,20220718T133500,https://www.globenewswire.com/news-release/2022/07/18/2481141/0/en/MIMEDX-Welcomes-Kate-Surdez-as-Chief-Human-Resources-Officer.html,AZN,0.205225,Neutral,0.128943
"Why Sentage Holdings Shares Are Trading Lower By 5%; Here Are 20 Stocks Moving Premarket - Alarum Technologies  ( NASDAQ:ALAR ) , ARB IOT Group  ( NASDAQ:ARBB ) ",20231226T130058,https://www.benzinga.com/news/23/12/36383191/why-sentage-holdings-shares-are-trading-lower-by-5-here-are-20-stocks-moving-premarket,AZN,0.077094,Somewhat-Bullish,0.196944
